ALLIANCES (Tables)

12 Months Ended

Dec. 31, 2018

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]

Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized. Certain prior period amounts included below were revised to exclude amounts for arrangements that no longer meet the criteria for collaboration arrangements.

	Year Ended December 31,
Dollars in Millions	2018			2017			2016
Revenues from alliances:
Net product sales	$	8,359		$	6,917		$	5,530
Alliance revenues	647			962			1,252
Total Revenues	$	9,006		$	7,879		$	6,782
Payments to/(from) alliance partners:
Cost of products sold	$	3,439		$	2,718		$	2,126
Marketing, selling and administrative	(104		)	(62		)	(30		)
Research and development	1,044			(28		)	(9		)
Other income (net)	(67		)	(46		)	(42		)

Selected Alliance Balance Sheet Information:	December 31,
Dollars in Millions	2018		2017
Receivables – from alliance partners	$	395	$	322
Accounts payable – to alliance partners	904		875
Deferred income from alliances(a)	491		467

(a) Includes unamortized upfront and milestone payments.

Collaborative Arrangement [Member] | Pfizer [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]

Summarized financial information related to this alliance was as follows:

	Year Ended December 31,
Dollars in Millions	2018			2017			2016
Revenues from Pfizer alliance:
Net product sales	$	6,329		$	4,808		$	3,306
Alliance revenues	109			64			37
Total Revenues	$	6,438		$	4,872		$	3,343
Payments to/(from) Pfizer:
Cost of products sold – Profit sharing	$	3,078		$	2,314		$	1,595
Other income (net) – Amortization of deferred income	(55		)	(55		)	(55		)

Selected Alliance Balance Sheet Information:	December 31,
Dollars in Millions	2018		2017
Receivables	$	220	$	193
Accounts payable	786		625
Deferred income	$	410	$	466

Collaborative Arrangement [Member] | Otsuka [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]

Summarized financial information related to this alliance was as follows:

	Year Ended December 31,
Dollars in Millions	2018		2017		2016
Revenues from Otsuka alliances:
Net product sales – Oncology territory	$	1,705	$	1,699	$	1,544
Payments to Otsuka:
Cost of products sold – Oncology fee	$	297	$	299	$	304

Collaborative Arrangement [Member] | Ono [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]

Summarized financial information related to this alliance was as follows:

	Year Ended December 31,
Dollars in Millions	2018		2017		2016
Revenues from Ono alliances:
Net product sales	$	165	$	145	$	147
Alliance revenues	294		268		280
Total Revenues	$	459	$	413	$	427

Collaborative Arrangement [Member] | Gilead [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]

Summarized financial information related to this alliance was as follows:

	Year Ended December 31,
Dollars in Millions	2018		2017		2016
Revenues from Gilead alliances:
Alliance revenues	$	253	$	623	$	934
Equity in net loss of affiliates	$	2	$	13	$	12

Collaborative Arrangement [Member] | AbbVie [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Table Text Block]

Summarized financial information related to this alliance was as follows:

	Year Ended December 31,
Dollars in Millions	2018		2017		2016
Revenues from AbbVie alliance:
Net product sales	$	162	$	150	$	132
Payments to AbbVie:
Cost of products sold – Profit sharing	$	44	$	41	$	34